Label Changes for:

Noroxin (norfloxacin) Tablets

March 2013

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)  

 

 

March 2013

ADVERSE REACTIONS

Postmarketing Experience
  • muscle spasms

 

 

June 2012 

 

ADVERSE REACTIONS

Post-marketing
  • DRESS (drug rash with eosinophilia and systemic symptoms) syndrome
 
Advertisement
Close

Recommended

(web6)